|Bid||6,200.00 x 6100|
|Ask||6,480.00 x 13000|
|Day's Range||6,254.26 - 6,432.48|
|52 Week Range||4,544.50 - 6,432.48|
|Beta (3Y Monthly)||1.27|
|PE Ratio (TTM)||33.07|
|Earnings Date||Feb 14, 2019|
|Forward Dividend & Yield||2.02 (3.23%)|
|1y Target Est||79.54|
AstraZeneca stock jumped Tuesday after the U.K.-based pharma giant said it would sell the U.S. rights to infant respiratory drug for $1.5 billion.
AstraZeneca (AZN) to sell U.S. rights of Synagis to Sobi for an upfront consideration of $1.5 billion as it streamlines its portfolio
PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.
Does AstraZeneca plc (ADR) (NYSE:AZN) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and invest millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]
AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.
AstraZeneca's deal to sell the U.S. rights to Synagis to a Swedish biopharmaceutical company is expected to be finalized early next year.
Sobi, officially Swedish Orphan Biovitrum AB, also gained the right to share the U.S. profits and losses on a potential new medicine, which Astra is developing with Sanofi, that targets the same lung virus Synagis treats, the Cambridge, England-based company said in a statement. Chief Executive Officer Pascal Soriot has been paring back Astra’s portfolio, selling the rights to fading blockbusters such as Nexium for reflux as a new crop emerges, led by Imfinzi and other cancer drugs.
AG said earnings fell sharply in the third quarter, in part as a result of a one-off gain booked in the prior year, while the number of glyphosate-related lawsuits it faces rose. Aftertax profit at the German chemical maker was 2.89 billion euros ($3.26 billion) compared with EUR3.88 billion a year earlier. DCC PLC said pretax profit in the first half of fiscal 2019 rose 17% and it continues to expect the full year to see more profit growth.
AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the treatment Synagis in the United States.
AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a serious infant lung infection to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the drug Synagis in the United States. Sobi also gets the right to participate in AstraZeneca's share of U.S. profits and losses in a follow-on drug for respiratory syncytial virus, called MEDI8897, which AstraZeneca is developing with Sanofi, the companies said.
Approval would expand use of AstraZeneca and MSD’s LYNPARZA to patients in the 1st-line setting following platinum-based chemotherapy
Fewer MACE events observed with FARXIGA vs. placebo, but this finding did not reach statistical significance
The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. Diabetics are at increased risk of heart problems, making the CV profile of drugs to treat the condition an important focus for doctors and patients.
has markedly reduced the chances of diabetic patients being hospitalised with heart failure, a condition associated with type 2 diabetes. The findings, from a large clinical trial, represent a significant boost for the Anglo-Swedish drugmaker which is striving to meet ambitious revenue targets. Cardio-vascular complications are common in people who contract type 2 diabetes, which has become a major burden on health systems worldwide.
GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace. Charlie Ripley, senior investment strategist at Allianz Investment Management said that, “With no press conference or expectation for policy change, most market participants viewed the November FOMC meeting as more of a non-event. “With only minimal changes to the statement the Fed is remaining vague about policy changes going forward and likely giving the committee more optionality in a changing market environment,” he added.
This article is from today’s FT Opinion email. Sign up to receive a daily digest of the big issues straight to your inbox. Does Europe have a strategy for coping with Donald Trump? His “America First” ...
AstraZeneca stock broke out Thursday after the pharma reported sales growth, claiming the quarter to be the beginning of continued growth.
A strong update by heavyweight drugmaker AstraZeneca (AZN.L) lifted Britain's benchmark index above European peers on Thursday as a global rally that followed the midterm U.S. elections faded. The FTSE 100 (.FTSE) rose 0.2 percent and the Euro Stoxx (.STOXXE) fell by 0.4 percent while Wall Street opened in slightly negative territory. AstraZeneca (AZN.L) rose 4 percent after strong demand for its new drugs - especially those for cancer - drove a return to sales growth in the third quarter and the drugmaker said it now anticipated years of sustained improvement.
Pascal Soriot, the CEO of European pharma giant AstraZeneca, believes that now the Democrats have won back control of the House of Representatives, they will "have to work collaboratively with the (President Donald Trump) administration. "We will see what they come up with," he told CNBC's "Squawk Box Europe" on Thursday. AstraZeneca is a biopharmaceutical company with a market capitalization of around $100 billion.
Strong demand for AstraZeneca's (AZN.L) new drugs -- especially those for cancer -- drove a return to sales growth in the third quarter and the drugmaker said it anticipated years of sustained improvement and rising profit margins. Product sales in the three months rose 8 percent, or 9 percent in constant currencies, which is the benchmark AstraZeneca uses for measuring the return to growth that it has been promising for 2018. It is the first quarter of sustainable product sales growth since 2014 and shares in the group, which resisted a takeover bid by Pfizer (PFE.N) in 2014, rose more than 5 percent to hit a record high of 61.85 pounds on Thursday.
AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.
The Cambridge, Britain-based company said it had profit of 34 cents per share. Earnings, adjusted for amortization costs and restructuring costs, came to 71 cents per share. The results topped Wall Street ...